Global growth investor Warburg Pincus has acquired Pharma Intelligence, a provider of specialist intelligence, data, and software for clinical trials, drug development, and regulatory compliance, from Informa, an international B2B markets knowledge services and business intelligence group.
Mubadala Investment Company, the Abu Dhabi based investment company, joins Warburg Pincus in the investment. The investors plan to extend the company’s position in the pharmaceutical data and analytics market, investing in the creation of innovative products for its customers. Informa will retain a 15 per cent stake in the company.
The acquisition includes Informa’s full portfolio of specialist brands which includes the Citeline suite of products, Trialtrove, Sitetrove, Pharmaprojects and Citeline branded products, as well as Biomedtracker, Clinerion, Datamonitor Healthcare, Pink Sheet, Scrip, Skipta, and TrialScope.
Read more: Private Equity Wire
Can't stop reading? This and all news articles are property of their creators, many are not owned or provided by Private Equity Insider. As an event organizer and community platform, we curate content from reliable sources for your suggested reading, and advise you to read the full articles from the referenced authors and sources.